ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Investor Conference Call:
ChromaDex management will host an investor conference call to discuss first quarter 2023 results and provide a general business update on Wednesday, May 10, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
Date: Wednesday, May 10, 2023
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-330-2446
Conference ID: 4126168
Webcast link: ChromaDex First Quarter 2023 Earnings Conference Call
The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.
A replay of the conference call will be available from 7:30 p.m. ET on May 10, 2023, to 11:59 p.m. ET on May 17, 2023.
Toll-free replay number: 1-800-770-2030
Replay ID: 4126168
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional financial information about the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005490/en/
ChromaDex Media Contact:
Kendall Knysch, Director of Media Relations
+1 (310) 388-6706 ext. 689
Kendall.Knysch@ChromaDex.com
ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com
Source: ChromaDex Corporation
